AbbVie unsurprisingly walked away from its partnership with Infinity after disappointing Phase II results for the PI3K inhibitor duvelisib. Another 100 Infinity employees will lose their jobs as the company conserves its cash and amends its clinical trial plan.
Infinity Pharmaceuticals Inc. has cut 100 more jobs in the wake of its disappointing Phase II DYNAMO clinical trial for the PI3K inhibitor duvelisib in indolent non-Hodgkin lymphoma (iNHL) now that the inevitable has happened: AbbVie Inc. exercised its right to end the companies' collaboration to develop the drug.
Cambridge, Massachusetts-based Infinity said it would lay off 58% of its staff in light of what was described as a...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
